Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human ...

IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.

PORTLAND, HI, UNITED STATES, September 17, 2024 /EINPresswire / -- The global protein therapeutics <a target=_blank href= ...

Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows: Effect of nomlabofusp administration on ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

Proinsulin-transferrin (ProINS-Tf) fusion protein was evaluated for its in vivo pharmacokinetics, efficacy, and mechanism. Our previous studies have shown that ProINS-Tf was converted to active ...

using a protein fusion strategy. T. gondii cell lines were engineered to express a therapeutic protein fused to the T. gondii secretory organelle proteins toxofilin or GRA16, to target fusion ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Kim, J. and Sadiora, K. (2024) Systematic Analysis of Post-Translational Modifications for Increased Longevity of ...